Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Dueñas, Marta ^a   Santos, Mirentxu ^a   Aranda, Juan F ^a   Bielza, Concha ^b   Martínez Cruz, Ana B ^a   Lorz, Corina ^a   Taron, Miquel ^c   Ciruelos, Eva M ^d   Rodríguez Peralto, José L ^e   Martín, Miguel ^f   Larrañaga, Pedro ^b   Dahabreh, Jubrail ^g   Stathopoulos, George P ^h   Rosell, Rafael ^c   Paramio, Jesús M ^a   García Escudero, Ramón ^a  

^a CIEMAT   (Spain)

^b UNIVERSIDAD POLITÉCNICA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e Instituto de Investigación Hospital 12 de Octubre i+12 Universidad Complutense ^*  (Spain)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g ATHENS MEDICAL CENTER   (Greece)

^h Errikos Dunant Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER GENETICS; CANCER MODEL; CANCER PATIENT; CONTROLLED STUDY; GENE EXPRESSION; GENETIC MARKER; GENOMICS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; SKIN CARCINOMA; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GENETIC ENGINEERING; GENOME, HUMAN; GENOMICS; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SKIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE; MUS MUSCULUS;

EID: 84864722013     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042494     Document Type: Article

References (70)

1. Yu X, Vazquez A, Levine Arnold J, Carpizo Darren R, (2012) Allele-Specific p53 Mutant Reactivation. Cancer cell 21: 614-625.
2. Mandinova A, Lee SW, (2011) The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 3: 64rv61.
3. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
4. van't Veer LJ, Bernards R, (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564-570.
5. Bild AH, Potti A, Nevins JR, (2006) Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 6: 735-741.
6. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, et al. (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2: E7.
7. Desai KV, Xiao N, Wang W, Gangi L, Greene J, et al. (2002) Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 99: 6967-6972.
8. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
9. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, et al. (2007) Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 67: 8065-8080.
10. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, et al. (2009) Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 4: e5401.
11. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17: 547-559.
12. Garcia-Escudero R, Martinez-Cruz AB, Santos M, Lorz C, Segrelles C, et al. (2010) Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy. Mol Cancer 9: 193.
13. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, et al. (2008) Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68: 683-692.
14. Mizuno H, Spike BT, Wahl GM, Levine AJ, (2010) Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A 107: 22745-22750.
15. Bornachea O, Santos M, Martinez-Cruz AB, Garcia-Escudero R, Duenas M, et al. (2012) EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep 2: 434.
16. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, et al. (2009) Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A 106: 16387-16392.
17. Eilon T, Barash I, (2009) Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5. BMC Genomics 10: 231.
18. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, et al. (2010) Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468: 572-575.
19. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810.
20. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, et al. (2011) Identification of early molecular markers for breast cancer. Mol Cancer 10: 15.
21. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000-3010.
22. Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, et al. (2011) Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin Appl 5: 179-188.
23. Zhu M, Yi M, Kim CH, Deng C, Li Y, et al. (2011) Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biol 12: R77.
24. Hurd C, Dinda S, Khattree N, Moudgil VK, (1999) Estrogen-dependent and independent activation of the P1 promoter of the p53 gene in transiently transfected breast cancer cells. Oncogene 18: 1067-1072.
25. Sayeed A, Konduri SD, Liu W, Bansal S, Li F, et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res 67: 7746-7755.
26. Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, et al. (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res 69: 3405-3414.
27. Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH, et al. (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239: 617-620.
28. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
29. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
30. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
31. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, et al. (2011) Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 17: 2591-2601.
32. Neale G, Su X, Morton CL, Phelps D, Gorlick R, et al. (2008) Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14: 4572-4583.
33. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, et al. (2010) Molecular target class is predictive of in vitro response profile. Cancer Res 70: 3677-3686.
34. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
35. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, et al. (2012) Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell 149: 1284-1297.
36. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
37. Lens SM, Voest EE, Medema RH, (2010) Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10: 825-841.
38. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W, (2008) Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68: 8998-9004.
39. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, et al. (2010) Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 9: 2079-2089.
40. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, et al. (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 106: 3964-3969.
41. Sotiriou C, Pusztai L, (2009) Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
42. Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB, (1995) Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Differ 6: 737-748.
43. Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, et al. (2008) Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 27: 5373-5384.
44. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
45. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, et al. (2005) Mining for regulatory programs in the cancer transcriptome. Nat Genet 37: 579-583.
46. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
47. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, et al. (2012) Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A 109: 2778-2783.
48. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
49. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, et al. (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
50. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
51. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
52. Chen R, Li L, Butte AJ, (2007) AILUN: reannotating gene expression data automatically. Nat Methods 4: 879.
53. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
54. Silvey SD, (1959) The Lagrangian Multiplier Test. Annals of Mathematical Statistics 30: 389-407.
55. Wald A, (1943) Tests of Statistical Hypotheses Concerning Several Parameters When the Number of Observations is Large. Transactions of the American Mathematical Society 54: 426-482.
56. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
57. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, et al. (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. Jama 305: 1873-1881.
58. Kao KJ, Chang KM, Hsu HC, Huang AT, (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143.
59. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246.
60. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
61. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-964.
62. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68: 5405-5413.
63. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28: 4111-4119.
64. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
65. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, et al. (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116: 303-309.
66. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, et al. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7: 59.
67. Nguyen DX, Bos PD, Massague J, (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
68. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, et al. (2009) Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 27: 2793-2799.
69. Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, et al. (2009) Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 10: 424.
70. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9: 166-180.